Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis.
Neuwirt E, Magnani G, Ćiković T, Wöhrle S, Fischer L, Kostina A, Flemming S, Fischenich NJ, Saller BS, Gorka O, Renner S, Agarinis C, Parker CN, Boettcher A, Farady CJ, Kesselring R, Berlin C, Backofen R, Rodriguez-Franco M, Kreutz C, Prinz M, Tholen M, Reinheckel T, Ott T, Groß CJ, Jost PJ, Groß O. Neuwirt E, et al. Among authors: boettcher a. Sci Signal. 2023 Jan 17;16(768):eabh1083. doi: 10.1126/scisignal.abh1083. Epub 2023 Jan 17. Sci Signal. 2023. PMID: 36649377
Pharmacological inhibition of IKKβ dampens NLRP3 inflammasome activation after priming in the human myeloid cell line THP-1.
Unterreiner A, Rubert J, Kauffmann M, Fruhauf A, Heiser D, Erbel P, Schlapbach A, Eder J, Bodendorf U, Boettcher A, Farady CJ, Bornancin F. Unterreiner A, et al. Among authors: boettcher a. Biochem Biophys Res Commun. 2021 Mar 19;545:177-182. doi: 10.1016/j.bbrc.2021.01.051. Epub 2021 Feb 6. Biochem Biophys Res Commun. 2021. PMID: 33561652
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Velcicky J, Janser P, Gommermann N, Brenneisen S, Ilic S, Vangrevelinghe E, Stiefl N, Boettcher A, Arnold C, Malinverni C, Dawson J, Murgasova R, Desrayaud S, Beltz K, Hinniger A, Dekker C, Farady CJ, Mackay A. Velcicky J, et al. Among authors: boettcher a. J Med Chem. 2024 Jan 25;67(2):1544-1562. doi: 10.1021/acs.jmedchem.3c02098. Epub 2024 Jan 4. J Med Chem. 2024. PMID: 38175811
Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation.
Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, Agrawal M, Farady CJ, Boettcher A, Hergott CB, McConkey M, Flores-Bringas P, Shkolnik V, Bick AG, Milan D, Natarajan P, Libby P, Ellinor PT, Ebert BL. Lin AE, et al. Among authors: boettcher a. Circulation. 2024 Apr 30;149(18):1419-1434. doi: 10.1161/CIRCULATIONAHA.123.065597. Epub 2024 Feb 15. Circulation. 2024. PMID: 38357791 Free PMC article.
Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches.
Vulpetti A, Rondeau JM, Bellance MH, Blank J, Boesch R, Boettcher A, Bornancin F, Buhr S, Connor LE, Dumelin CE, Esser O, Hediger M, Hintermann S, Hommel U, Koch E, Lapointe G, Leder L, Lehmann S, Lehr P, Meier P, Muller L, Ostermeier D, Ramage P, Schiebel-Haddad S, Smith AB, Stojanovic A, Velcicky J, Yamamoto R, Hurth K. Vulpetti A, et al. Among authors: boettcher a. J Med Chem. 2024 May 23;67(10):8141-8160. doi: 10.1021/acs.jmedchem.4c00240. Epub 2024 May 10. J Med Chem. 2024. PMID: 38728572
Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β.
Hommel U, Hurth K, Rondeau JM, Vulpetti A, Ostermeier D, Boettcher A, Brady JP, Hediger M, Lehmann S, Koch E, Blechschmidt A, Yamamoto R, Tundo Dottorello V, Haenni-Holzinger S, Kaiser C, Lehr P, Lingel A, Mureddu L, Schleberger C, Blank J, Ramage P, Freuler F, Eder J, Bornancin F. Hommel U, et al. Among authors: boettcher a. Nat Commun. 2023 Sep 7;14(1):5497. doi: 10.1038/s41467-023-41190-0. Nat Commun. 2023. PMID: 37679328 Free PMC article.
101 results